DMAC DiaMedica Therapeutics, Inc.

3.910.07 (+1.82%)
15 minute delayed price: 12:11:42 PM

Quote

Previous Close
$3.71
Day Range
$3.75-$4.03
52 Week Range
$2.46-$12.02
Volume
12,886
Avg Volume
203,399
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$614.41M
Enterprise Value (EV)
$586.61M
PE Ratio
-
EV/EBITDA
-91.86
Price/Sales
-
Price/Book
35.44
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$6.39M
EPS, ttm
-$0.81
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/28/2019 (41 days)
Debt to Equity
-
Debt
-
Cash
$16.82M
Net Debt
-

Performance

Beta
1.52
200 Day Moving Avg
$4.33
50 Day Moving Avg
$3.62
52 Week Change
-67.29%
YTD Change
20.71%
1 Month Change
0.52%
3 Month Change
-2.78%
6 Month Change
5.53%
1 Year Change
-67.29%
2 Year Change
-35.01%
5 Year Change
-75.43%

Share Count

Shares Outstanding
157.1M
Float
-
Restricted Shares
157.1M
Restricted Shares, %
100.00%

DiaMedica Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Rick John Pauls

Website: http://www.diamedica.com

Description: DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Employees: 9